Clorox (CLX) Given a $131.00 Price Target by Barclays Analysts

Barclays set a $131.00 target price on Clorox (NYSE:CLX) in a research report sent to investors on Saturday morning. The firm currently has a hold rating on the stock.

Other analysts also recently issued research reports about the company. UBS Group assumed coverage on Clorox in a research note on Wednesday, July 18th. They set a sell rating and a $110.00 price target for the company. BMO Capital Markets reiterated a buy rating and set a $153.00 price target on shares of Clorox in a research note on Friday, August 3rd. ValuEngine upgraded Clorox from a hold rating to a buy rating in a research note on Saturday, September 22nd. Zacks Investment Research upgraded Clorox from a hold rating to a buy rating and set a $171.00 price target for the company in a research note on Wednesday. Finally, Argus upgraded Clorox from a hold rating to a buy rating and set a $175.00 price target for the company in a research note on Tuesday, September 25th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $137.00.

NYSE CLX traded up $3.00 on Friday, reaching $149.58. The stock had a trading volume of 1,559,896 shares, compared to its average volume of 1,205,527. The company has a debt-to-equity ratio of 3.15, a current ratio of 1.09 and a quick ratio of 0.67. Clorox has a 1 year low of $113.57 and a 1 year high of $153.38. The company has a market capitalization of $19.21 billion, a P/E ratio of 23.89, a price-to-earnings-growth ratio of 3.11 and a beta of 0.36.

Clorox (NYSE:CLX) last released its quarterly earnings results on Thursday, August 2nd. The company reported $1.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.08. The company had revenue of $1.69 billion during the quarter, compared to the consensus estimate of $1.72 billion. Clorox had a return on equity of 103.18% and a net margin of 13.44%. The firm’s revenue was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.53 EPS. On average, equities analysts anticipate that Clorox will post 6.41 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 16th. Investors of record on Wednesday, October 31st will be given a dividend of $0.96 per share. The ex-dividend date is Tuesday, October 30th. This represents a $3.84 annualized dividend and a dividend yield of 2.57%. Clorox’s dividend payout ratio is presently 61.34%.

In other Clorox news, SVP Michael R. Costello sold 9,265 shares of the company’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $140.02, for a total value of $1,297,285.30. Following the completion of the transaction, the senior vice president now owns 34,293 shares of the company’s stock, valued at approximately $4,801,705.86. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Linda J. Rendle sold 382 shares of the company’s stock in a transaction that occurred on Thursday, September 6th. The shares were sold at an average price of $148.32, for a total value of $56,658.24. The disclosure for this sale can be found here. Insiders have sold a total of 29,268 shares of company stock valued at $4,196,686 in the last three months. 1.00% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of the business. Cornerstone Wealth Management LLC bought a new position in Clorox in the 2nd quarter valued at $105,000. Ostrum Asset Management bought a new position in Clorox in the 1st quarter valued at $112,000. Fort L.P. bought a new position in Clorox in the 2nd quarter valued at $129,000. Whittier Trust Co. of Nevada Inc. boosted its position in Clorox by 1,297.4% in the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 1,621 shares of the company’s stock valued at $148,000 after buying an additional 1,505 shares during the last quarter. Finally, IMS Capital Management bought a new position in Clorox in the 2nd quarter valued at $161,000. 78.36% of the stock is owned by hedge funds and other institutional investors.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

See Also: How to Track your Portfolio in Google Finance

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply